alisporivir and Pneumonia--Viral

alisporivir has been researched along with Pneumonia--Viral* in 1 studies

Other Studies

1 other study(ies) available for alisporivir and Pneumonia--Viral

Article	Year
Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7 Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Cyclophilins; Cyclosporine; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vero Cells; Virus Replication	2020

Article

Year

Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).

Antimicrobial agents and chemotherapy, 2020, 06-23, Volume: 64, Issue:7

Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC

Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Cyclophilins; Cyclosporine; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vero Cells; Virus Replication

2020